These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 20166997)

  • 41. Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies.
    Miller NA; Reddy MB; Heikkinen AT; Lukacova V; Parrott N
    Clin Pharmacokinet; 2019 Jun; 58(6):727-746. PubMed ID: 30729397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heart-on-Chip for Combined Cellular Dynamics Measurements and Computational Modeling Towards Clinical Applications.
    Park J; Wu Z; Steiner PR; Zhu B; Zhang JXJ
    Ann Biomed Eng; 2022 Feb; 50(2):111-137. PubMed ID: 35039976
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug testing and characterization using human-on-chip (HoC) systems: some thoughts on the application of in vitro-in vivo correlation.
    Somayaji MR; Das D; Przekwas AJ
    Drug Discov Today; 2018 Sep; 23(9):1571-1573. PubMed ID: 29428643
    [No Abstract]   [Full Text] [Related]  

  • 45. Fabrication and Applications of Microfluidic Devices: A Review.
    Niculescu AG; Chircov C; Bîrcă AC; Grumezescu AM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods.
    Tsaioun K; Blaauboer BJ; Hartung T
    ALTEX; 2016; 33(4):343-358. PubMed ID: 27806179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
    Poulin P; Jones HM; Jones RD; Yates JW; Gibson CR; Chien JY; Ring BJ; Adkison KK; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Ku MS
    J Pharm Sci; 2011 Oct; 100(10):4050-73. PubMed ID: 21523782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Next generation human skin constructs as advanced tools for drug development.
    Abaci HE; Guo Z; Doucet Y; Jacków J; Christiano A
    Exp Biol Med (Maywood); 2017 Nov; 242(17):1657-1668. PubMed ID: 28592171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic screening strategy for discovery work-use of rodent species: lessons learnt and probing newer thoughts.
    Srinivas NR
    Drug Metab Pharmacokinet; 2009; 24(2):197-8. PubMed ID: 19430178
    [No Abstract]   [Full Text] [Related]  

  • 51. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
    De Buck SS; Mackie CE
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):865-78. PubMed ID: 18028030
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Microfluidic cell culture systems for drug research.
    Wu MH; Huang SB; Lee GB
    Lab Chip; 2010 Apr; 10(8):939-56. PubMed ID: 20358102
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comprehensive assessment of ADMET risks in drug discovery.
    Wang J
    Curr Pharm Des; 2009; 15(19):2195-219. PubMed ID: 19601823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach.
    Mayumi K; Ohnishi S; Hasegawa H
    J Pharm Sci; 2019 Aug; 108(8):2718-2727. PubMed ID: 30876861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling.
    Sung JH; Esch MB; Shuler ML
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1063-81. PubMed ID: 20540627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early prediction of drug metabolism and toxicity: systems biology approach and modeling.
    Bugrim A; Nikolskaya T; Nikolsky Y
    Drug Discov Today; 2004 Feb; 9(3):127-35. PubMed ID: 14960390
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multi-organ-on-a-chip for pharmacokinetics and toxicokinetic study of drugs.
    Sung JH
    Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):969-986. PubMed ID: 33764248
    [No Abstract]   [Full Text] [Related]  

  • 58. [Rapid pharmacokinetics screening of drug candidates in vitro and in vivo].
    Dong XN; Zhu XX; Meng ZY; Liu JL; Cao YL; Dou GF
    Yao Xue Xue Bao; 2009 Nov; 44(11):1309-12. PubMed ID: 21355332
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of exploratory drug metabolism and pharmacokinetics in new drug research: case study-selection of a thrombin receptor antagonist for development.
    Hsieh Y; Cheng KC; Wang Y; Chackalamannil S; Xia Y; Korfmacher WA; White RE
    Curr Pharm Des; 2009; 15(19):2262-9. PubMed ID: 19601827
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development.
    Karlsson FH; Bouchene S; Hilgendorf C; Dolgos H; Peters SA
    Drug Metab Dispos; 2013 Dec; 41(12):2033-46. PubMed ID: 23918667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.